At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 211 enrolled
Drug / intervention
Valsartan +1 moredrug
Likely dose
Valsartan 160 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
In Brief
A Phase 2 clinical trial evaluating Valsartan and Placebo for Hypertrophic Cardiomyopathy. Completed, enrolled 211 participants across 15 sites in 2 countries.
Detailed Summary
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertrophic Cardiomyopathy
CountriesCanada, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartMar 2014
Primary CompletionJul 2019
TodayJul 2026
First PostedJul 31, 2013
Enrollment StartMar 1, 2014
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.9 years ago
Interventions
Valsartandrug
40, 80 and 160 mg tablets of Valsartan
Placebodrug
During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo